Click it and Unblock the Notifications
Latest Updates
-
Amitabh Bachchan's Misunderstood Blog Sparked Concern, But His Real Medical Battles Define Resilience -
Jaipur Ranks 6th Among World's Happiest Cities 2026: The Culture Behind The Joy -
Why Green Is the Colour of Sawan: History, Symbolism, and Styling Tips -
Legionnaires' Disease Outbreak: What It Is, Symptoms, Causes, And Prevention Explained -
Ananya Panday's Gaurav Gupta Couture Featured 12,000 Pearls, 2,600 Petals And A Celestial Love Story -
Kharchi Puja 2026: Tripura's Ancient Festival Where The Heads Of Fourteen Deities Are Worshipped -
World Brain Day 2026: How Quality Sleep Helps Safeguard Your Brain Health -
National Mango Day 2026: Why Mango Is Called The 'King Of Fruits' And What Sets It Apart -
Is It Monsoon Hair Fall Or Something More Serious? How To Tell -
World Brain Day 2026: Date, History, Theme, and Why It Matters
DCGI Approves India's First qHPV Vaccine Against Cervical Cancer
Update: As per recent news reports, the DCGI subject expert committee has approved Serum Institute's indigenously created qHPV vaccination for cervical cancer. It will be India's first indigenous cervical cancer vaccine.
Serum Institute of India (SII) has applied to the country's drug regulator seeking market authorisation to manufacture indigenously developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said on Wednesday, June 8.
The Pune-based firm has applied for market authorisation after completing the phase 2/3 clinical trial with support of the Department of Biotechnology to ensure its early availability in the country, they said.
In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, director (government and regulatory affairs) at SII, said the vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
The SII is also learnt to have made a presentation before the working group of HPV under the chairmanship of Dr NK Arora constituted separately by the NTAGI to review the data and usefulness of this vaccine on Wednesday, the sources said.
In the application, Singh mentioned that every year lakhs of women are diagnosed with cervical cancer as well as few other cancers and death ratio is also very high.
Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.
"Also, it is noteworthy that presently, our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group & under the leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high quality 'Made in India' vaccines at an affordable price for people of our country and the world at large," Singh said in the application.
"Like many other indigenous life-saving vaccines, we are committed to making our country 'ATMANIRBHAR' for India's first indigenous life-saving qHPV vaccine also. This will fulfill the dream of our Hon'ble Prime Minister Narendra Modi 'VOCAL FOR LOCAL' and 'MAKING IN INDIA FOR THE WORLD' and will ensure the prevention of cancers caused by Human Papillomavirus (Type 6, 11, 16 & 18) vaccine recombinant," Singh is learnt to have said in the application.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google